Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2003
10/16/2003WO2003084995A2 Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
10/16/2003WO2003084988A2 Cd4+ t-lymphocyte-specific hepatitis c virus epitopes
10/16/2003WO2003084979A2 Novel peptides and the application thereof in therapy
10/16/2003WO2003084570A1 DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
10/16/2003WO2003084568A2 Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations
10/16/2003WO2003084560A2 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
10/16/2003WO2003084540A2 Compositions comprising mmp7 modulators for the treatment of chronic pain
10/16/2003WO2003084472A2 Recombinant p. falciparum merozoite protein-142 vaccine
10/16/2003WO2003084470A2 Compositions and methods for targeted biological delivery of molecular carriers
10/16/2003WO2003084467A2 Epitope constructs comprising antigen presenting cell targeting mechanisms
10/16/2003WO2003068954A3 Microorganism for genetic therapeutic treatment of proliferative diseases
10/16/2003WO2003068813A3 Group b streptococcus antigen
10/16/2003WO2003064595A3 Recombinant herpesvirus of turkeys and use thereof
10/16/2003WO2003063792A8 Compositions and methods related to tim-3, a th1-specific cell surface molecule
10/16/2003WO2003059282A3 Human monoclonal antibodies against cd30
10/16/2003WO2003054216A3 Antibodies that immunospecifically bind to trail receptors
10/16/2003WO2003051393A3 Enzymatic cleavable reagents for specific delivery to disease sites
10/16/2003WO2003050064A3 Mitotic kinesin inhibitors
10/16/2003WO2003048321A3 Hybrid antibodies
10/16/2003WO2003046560B1 Self-assembly molecules
10/16/2003WO2003038062A3 Generation of use of tc1 and tc2 cells
10/16/2003WO2003035835A3 Glycoprotein compositions
10/16/2003WO2003035003A3 Fused cells, methods of forming same, and therapie utilizing same
10/16/2003WO2003029434A3 Novel molecules of the hkid-1-related protein family and uses thereof
10/16/2003WO2003029413A3 A novel g protein-coupled receptor, gave 10
10/16/2003WO2003028638A3 Treatment of uterine serous papillary cancer
10/16/2003WO2003028634A3 Method of treatment using ligand-immunogen conjugates
10/16/2003WO2003025127A3 Chromogenic in situ hybridization methods, kits, and compositions
10/16/2003WO2003024993A3 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
10/16/2003WO2003014154A3 Vaccines against kaposi's sarcoma-associated herpesvirus
10/16/2003WO2003011907A3 Receptor, the use thereof, and mouse antibodies
10/16/2003WO2003011342A3 Targeted polymeric delivery systems
10/16/2003WO2003006055A9 Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit
10/16/2003WO2003004520A3 Mycobacterial antigens expressed during latency
10/16/2003WO2002102307A3 Nucleoside vaccine adjuvants
10/16/2003WO2002098899A3 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
10/16/2003WO2002077211A3 A virus (cryptovirus) within the rubulavirus genus and uses therefor
10/16/2003WO2002044384A3 T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy
10/16/2003WO2002029074A3 Genetic immunisation against cervical carcinoma
10/16/2003US20030195349 H. pylori flbA polypeptides, immunogenic and vaccinating compositions comprising H. pylori flbA polypeptides, and compositions for detection of an infection comprising H. pylori flbA polypeptides
10/16/2003US20030195337 UL16 binding protein 4
10/16/2003US20030195333 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030195148 Secreted and transmembrane polypeptides and nucleic acids encoding the same
10/16/2003US20030194804 For enhancing T cell response to tumour cells
10/16/2003US20030194801 Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
10/16/2003US20030194800 For immunization, generation of packaging cell lines, and production of immunogenic compositions
10/16/2003US20030194764 Compositions and methods for the therapy and diagnosis of lung cancer
10/16/2003US20030194763 End selection in directed evolution
10/16/2003US20030194761 Novel nucleic acid sequences encoding human fibroblast growth factor-like polypeptides
10/16/2003US20030194746 For diagnosis, prognosis, prophylaxis
10/16/2003US20030194739 Using cancer specific genes
10/16/2003US20030194737 Use of parapox B2L protein to modify immune responses to administered antigens
10/16/2003US20030194732 For treating neoplastic diseases by testing responsiveness to interferons
10/16/2003US20030194695 Nucleic acid and polypeptide sequences useful as adjuvants
10/16/2003US20030194694 Pure recombinant influenza virus comprising a mutant ion channel protein which lacks or has reduced activity relative to the wild-type
10/16/2003US20030194414 Replikin peptides and antibodies therefore
10/16/2003US20030194412 Emulsion comprising an aqueous phase, an oil phase, and a solvent and an immunogen
10/16/2003US20030194411 Peptide compositions for the treatment and prevention of HIV infection
10/16/2003US20030194408 Antibody which specifically binds to at least two variants of an epitope of an HIV-1 Tat protein
10/16/2003US20030194406 P-cadherin as a target for anti-cancer therapy
10/16/2003US20030194404 Gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules; especially for treating asthma and other respiratory system disorders
10/16/2003US20030194395 Th1 cell adoptive immunotherapy
10/16/2003US20030194393 Toxoplasma gondii proteins, nucleic acid molecules, and uses thereof
10/16/2003US20030194391 Vaccine
10/16/2003US20030192560 Method and apparatus for dosing single and multi-agent therapy
10/16/2003US20030192226 Animal decoy
10/16/2003CA2513149A1 A human ribonucleotide reductase m2 subunit
10/16/2003CA2481925A1 Therapeutic agent for patients having human fc.gamma.riiia
10/16/2003CA2481837A1 Production process for antibody composition
10/16/2003CA2481829A1 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
10/16/2003CA2481719A1 Modified cea nucleic acid and expression vectors
10/16/2003CA2481658A1 Method of enhancing of binding activity of antibody composition to fcy receptor iiia
10/16/2003CA2481318A1 Identification of virulence associated regions rd1 and rd5 leading to improve vaccine of m. bovis bcg and m. microti
10/16/2003CA2480996A1 Peptides derived or obtained from cytokine and the application thereof in therapy
10/16/2003CA2480786A1 Recombinant p. falciparum merozoite protein-142 vaccine
10/16/2003CA2480598A1 Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
10/16/2003CA2480504A1 Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
10/16/2003CA2480196A1 Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations
10/16/2003CA2480084A1 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
10/16/2003CA2479927A1 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
10/16/2003CA2478930A1 Epitope constructs comprising antigen presenting cell targeting mechanisms
10/16/2003CA2478901A1 Methods of virus production
10/16/2003CA2477298A1 Use of biomolecular targets in the treatment and visualization of brain tumors
10/15/2003EP1352956A1 Inhibition of DNA methyltransferase
10/15/2003EP1352092A2 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis
10/15/2003EP1352088A2 Genes comprising coding mononucleotide microsatellites or dinucleotide microsatellites that can be isolated from tumor cells
10/15/2003EP1352056A2 Polypeptides
10/15/2003EP1352053A2 Method for processing dendritic cells and for activating macrophages with ru 41740
10/15/2003EP1352052A1 Ancillary composition for the preparation of committed mature dentritic cells
10/15/2003EP1351989A2 Improved compositions and methods for producing antibodies to low molecular weight analytes
10/15/2003EP1351988A1 Group 2 allergen specific ige-fabs and igg molecules and use thereof
10/15/2003EP1351985A2 Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors
10/15/2003EP1351968A1 Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
10/15/2003EP1351967A2 Compositions and methods for the therapy and diagnosis of lung cancer
10/15/2003EP1351744A2 Erbb4 antagonists
10/15/2003EP1351709A2 Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
10/15/2003EP1351708A1 Therapeutic agent comprising a b-subunit of a protein toxin
10/15/2003EP1351707A2 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/15/2003EP1351702A1 Trem-1 splice variant for use in modifying immune responses
10/15/2003EP1351699A1 Methods for improved diagnosis and treatment of mycobacterial infections
1 ... 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 ... 1823